Vietnam has decided to extend the validity of marketing authorisations for European pharmaceuticals by 2 years, the European Commission said on Monday 20 February.
The decision, made on 8 February by the Vietnamese Ministry of Health, will facilitate the operations of EU exporters until at least December 2024, according to the Commission. The latter believes that the authorisation procedures in Vietnam have so far negatively affected the supply of European pharmaceuticals in that country.
A step had already been taken in October 2022, when Vietnam ended its differential treatment of Spanish, Polish, Italian and Hungarian pharmaceuticals (see EUROPE 13047/21). These were subject to longer registration procedures due to the fact that Vietnam differentiated the regulatory authorities in these four countries from the other 23 in the EU. (Original version in French by Léa Marchal)